Search
Flibanserin
go.drugbank.com/drugs/DB04908ApprovedInvestigationalFlibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. … in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.
Polyethylene glycol 400
go.drugbank.com/drugs/DB11077ApprovedInvestigationalIt is used in ophthalmic solutions for the relief of burning, irritation and/or discomfort that follows dryness of the eye [L1785]. … It is very hydrophilic, which renders it a useful ingredient in drug formulations to augment the solubility and bioavailability of weakly water-soluble drugs.
Mixtures: i-Drops LUBRICANT EYE DROPS, i-Drops LUBRICANT EYE DROPSCategories: Compounds used in a research, industrial, or household settingPorfimer sodium
go.drugbank.com/drugs/DB00707ApprovedInvestigationalIt is the first drug to be approved in the use of photodynamic therapy in the United States. … It is used in photodynamic therapy (hematoporphyrin photoradiation); to treat malignant lesions with visible light and experimentally as an antiviral agent.
Categories: Sensitizers Used in Photodynamic/radiation TherapyInternational brands: Photofrin IIRespiratory syncytial virus vaccine, adjuvanted
go.drugbank.com/drugs/DB17762ApprovedInvestigational[L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380] … It comprises lyophilized recombinant respiratory syncytial virus glycoprotein F (RSVPreF3) stabilized in pre-fusion conformation as the antigen component, which is reconstituted at the time of use with
Folitixorin calcium
go.drugbank.com/drugs/DB05308InvestigationalCoFactor use with 5-FU is being evaluated in clinical trials in first line treatment of metastatic colorectal cancer. … ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU).
Deucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigational[L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788] … [A246943] Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis.
Pirfenidone
go.drugbank.com/drugs/DB04951ApprovedInvestigational[A251370] It is an antifibrotic agent with anti-inflammatory and antioxidant properties [A251370] that is used to treat idiopathic pulmonary fibrosis (IPF),[L26801] which is a chronic, progressive form … Pirfenidone is a synthetic pyridone drug.
Atazanavir
go.drugbank.com/drugs/DB01072ApprovedInvestigationaland other fatty substances in the blood). … Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.
Categories: Antivirals used in combination for the treatment of HIV infectionsTriclocarban
go.drugbank.com/drugs/DB11155ApprovedIt is a bacteriostatic compound that has been found in antibacterial soaps and other personal care products. … In 2017, the US FDA prohibited the marketing of over-the-counter (OTC) consumer antiseptic wash products containing triclocarban due to negative health effects such as bacterial resistance or hormonal
Synonyms: N-(4-chlorophenyl)-N'-(3,4-dichlorophenyl)urea